Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Elisabeth E. Fransen van de Putte,Luna van den Brink, Mohamed A. Mansour,Johannes C. van der Mijn,Sofie Wilgenhof,Johannes V. van Thienen,John B.A.G. Haanen,Ekaterini Boleti,Thomas Powles,Patricia J. Zondervan,Niels M. Graafland,Axel Bex

European Urology Open Science（2023）

引用 1|浏览13

暂无评分

摘要

Following ipilimumab/nivolumab treatment, cytoreductive nephrectomy to achieve no evidence of disease resulted in durable disease-free survival and median treatment-free survival of 21 mo.

查看译文

关键词

deferred cytoreductive nephrectomy,systemic therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要